Leah Lawrence

Patients with working memory dysfunctions and depression may be more likely to be nonadherent to oral cancer therapies, according to the results of a study presented at ESMO.

Adding daratumumab to lenalidomide and dexamethasone significantly improved progression-free survival in patients with relapsed or refractory multiple myeloma.

The expansion of healthcare in Massachusetts in 2006 was associated with increased rates of resection for patients with colorectal cancer.

The use of an intensified treatment regimen to treat metastatic medulloblastoma in children and adolescents conferred an overall favorable survival, according to the results of a recent study. However, patients within varying subgroups and with certain biologic parameters did not have uniform outcomes.

Phase II data provide further evidence that patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion have a new treatment option with ibrutinib.

In children with primary brain tumors who were treated with cranial radiation, cerebral volume and radiation dose may affect the rate of vocabulary development.

The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).

More than 80% of patients referred for consideration in a phase I clinical trial were still willing to participate after a consultation where they learned more about trial participation.

Patients with Hodgkin lymphoma have a high incidence of severe acute and persistent fatigue, regardless of their tumor stage or the treatment method chosen for their disease.

Patients with metastatic RCC and a BMI of 25 or greater had significantly longer overall survival compared with patients with a BMI of less than 25, according to the results of a recent study.

The combination of bevacizumab and everolimus had efficacy in patients with unclassified non–clear cell renal cell carcinoma characterized by papillary features, resulting in an objective response rate of 43%.

Researchers have established estimates of occult nodal disease risk in patients after surgery for papillary thyroid cancer, using primary tumor stage and the number of lymph nodes examined.

Patients with advanced cancer treated with the peripheral μ-opioid receptor antagonist methylnaltrexone had longer overall survival.

The use of sunscreen with an SPF of 15 or greater was associated with about a 30% reduction in the risk for melanoma among a group of Norwegian women.

Use of lenalidomide monotherapy in patients with adult T-cell leukemia/lymphoma resulted in clinically meaningful antitumor activity, with 42% of phase II trial participants having objective responses.

Many adolescent girls with leukemia did not receive pregnancy screening before undergoing teratogenic exposure.

The use of telephone counseling for hereditary breast and ovarian cancer was noninferior to in-person counseling with no significant adverse effects on long-term outcomes.

The addition of carfilzomib to lenalidomide and dexamethasone improved health-related quality of life compared with treatment with lenalidomide/dexamethasone alone among patients with relapsed multiple myeloma enrolled in the ASPIRE trial.

Patients with RCC who underwent simultaneous nephrectomy and hepatic resection had similar postoperative mortality, long-term survival, and cancer-specific survival as those patients who underwent metastasectomy or en bloc resection of neighboring non-hepatic organs.

The quantification of a patient’s MRD after treatment for CLL allowed for a more specific prediction of progression-free survival among patients who responded to treatment.

Oral vitamin D intake was associated with an increased risk for basal cell carcinoma, but not melanoma, according to two large cohort studies.

Vinblastine monotherapy produced outcomes similar to current therapies in children with treatment-naive pediatric low-grade glioma, and had favorable toxicity and quality-of-life profiles.

Many patients who receive prescription drugs get them from dispensing physician practices. Since 2006, these dispensaries have participated as in-network providers for various Medicare Part D pharmacy networks; however, now physician dispensaries are in danger of being reclassified as out-of-network.

Adding the CD38-targeting monoclonal antibody daratumumab to bortezomib and dexamethasone resulted in significantly improved progression-free survival in patients with heavily pretreated multiple myeloma.

The International Agency for Research on Cancer Working Group recently released an updated evaluation of evidence connecting body fatness and cancer.

Although the overall incidence of programmed cell death 1 (PD-1) inhibitor-related pneumonitis is rare, the serious adverse event may occur more commonly in certain solid tumor types like non–small-cell lung cancer and renal cell carcinoma.

The use of electric power morcellation for hysterectomy has declined since the FDA warned that the procedure, which fragments the uterus into smaller pieces, may result in the spread of undetected malignancies.

The deferral of postoperative radiotherapy is increasing among children with medulloblastoma, and this deferral of treatment was associated with worse survival.

A gene expression microarray-based assay was able to successfully identify patients with stage II colon cancer who are at high risk for recurrence.

Socioeconomic factors affected the care and survival of younger patients with multiple myeloma, but race/ethnicity itself did not influence survival.